alexa The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Pharmaceutical Care & Health Systems

Author(s): Bunting BA, Smith BH, Sutherland SE

Abstract Share this page

Abstract OBJECTIVE: Assess clinical and economic outcomes of a community-based, long-term medication therapy management (MTM) program for hypertension (HTN)/dyslipidemia. DESIGN: Quasi-experimental, longitudinal, pre-post study. SETTING: 12 community and hospital pharmacy clinics in Asheville, N.C., over a 6-year period from 2000 through 2005. PARTICIPANTS: Patients covered by two self-insured health plans; educators at Mission Hospitals; 18 certificate-trained pharmacists. INTERVENTIONS: Cardiovascular or cerebrovascular (collectively abbreviated as CV) risk reduction education; regular, long-term follow-up by pharmacists (reimbursed by health plans) using scheduled consultations, monitoring, and recommendations to physicians. MAIN OUTCOME MEASURES: Clinical and economic parameters. RESULTS: Sufficient data were available for 620 patients in the financial cohort and 565 patients in clinical cohort. Several indicators of cardiovascular health improved over the course of the study: mean systolic blood pressure, from 137.3 to 126.3 mm Hg; mean diastolic blood pressure, from 82.6 to 77.8 mm Hg; percentage of patients at blood pressure goal, from 40.2\% to 67.4\%; mean low-density lipoprotein (LDL) cholesterol, from 127.2 to 108.3 mg/dL; percentage of patients at LDL cholesterol goal, from 49.9\% to 74.6\%; mean total cholesterol, from 211.4 to 184.3 mg/dL; and mean serum triglycerides, from 192.8 to 154.4 mg/dL. Mean high-density lipoprotein (HDL) cholesterol decreased from 48 to 46.6 mg/dL. The CV event rate during the historical period, 77 per 1,000 person-years, declined by almost one-half (38 per 1,000 person-years) during the study period. Mean cost per CV event in the study period was $9,931, compared with $14,343 during the historical period. During the study period, CV medication use increased nearly threefold, but CV-related medical costs decreased by 46.5\%. CV-related medical costs decreased from 30.6\% of total health care costs to 19\%. A 53\% decrease in risk of a CV event and greater than 50\% decrease in risk of a CV-related emergency department (ED)/hospital visit were also observed. CONCLUSION: Patients with HTN and/or dyslipidemia receiving education and long-term MTM services achieved significant clinical improvements that were sustained for as long as 6 years, a significant increase in the use of CV medications, and a decrease in CV events and related medical costs. This article was published in J Am Pharm Assoc (2003) and referenced in Journal of Pharmaceutical Care & Health Systems

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version